 <h1>Optison Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>perflutren</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about perflutren. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Optison.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to perflutren: intravenous suspension</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Suspension)</p><p>Serious cardiopulmonary reactions, including fatalities, have occurred during or following perflutren-containing microsphere administration with the most serious reactions occurring within 30 minutes of administration. Assess all patients for any condition that precludes use of this product. Always have resuscitation equipment and trained personnel available.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, perflutren (the active ingredient contained in Optison) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking perflutren:</p><p>
<i>Less common</i>
</p><ul>
<li>Chest pain</li>
<li>feeling of warmth</li>
<li>fever or chills</li>
<li>redness of the face, neck, arms, and occasionally, upper chest</li>
<li>trouble breathing</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Hives or welts, itching, or skin rash</li>
<li>fast, irregular, pounding, or racing heartbeat or pulse</li>
<li>redness of the skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blurred vision</li>
<li>chest discomfort</li>
<li>cold, clammy skin</li>
<li>confusion</li>
<li>convulsions</li>
<li>dizziness</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly  from a lying or sitting position</li>
<li>fainting</li>
<li>fast, pounding, or irregular heartbeat or pulse</li>
<li>fast, weak pulse</li>
<li>feeling of warmth</li>
<li>headache</li>
<li>hoarseness</li>
<li>irritation</li>
<li>joint pain, stiffness, or swelling</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>lightheadedness, dizziness, or fainting</li>
<li>nervousness</li>
<li>no blood pressure or pulse</li>
<li>noisy breathing</li>
<li>pounding in the ears</li>
<li>redness of the face, neck, arms, and occasionally, upper chest</li>
<li>stopping of heart</li>
<li>sweating</li>
<li>tightness in the chest</li>
<li>troubled swallowing</li>
<li>unconsciousness</li>
<li>unusual tiredness or weakness</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of perflutren may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Bad, unusual, or unpleasant (after) taste</li>
<li>change in taste</li>
<li>cough</li>
<li>discomfort at the injection site</li>
<li>nausea or vomiting</li>
<li>sore throat</li>
<li>stuffy or runny nose</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Back pain</li>
<li>body or muscle aches</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>change in color vision</li>
<li>continuing ringing or buzzing or other unexplained noise in the ears</li>
<li>difficulty with moving</li>
<li>difficulty seeing at night</li>
<li>discoloration of the skin at the injection site</li>
<li>dry mouth</li>
<li>hearing loss</li>
<li>increased sensitivity of the eyes to sunlight</li>
<li>muscle pain or stiffness</li>
</ul><p>
<!-- end intravenous suspension --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to perflutren: intravenous suspension</i></p><h3>General</h3><p>The most frequently reported adverse reactions were headache, nausea and/or vomiting, warm sensation or flushing, dizziness, and back pain.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Serious but uncommon cardiopulmonary reactions, including fatalities, have been reported during or following administration of this medication.  Most serious reactions occurred within 30 minutes of administration.</p>
<p></p>
<p>QTc prolongation of greater than 30 milliseconds occurred in 29% (64/221) of patients evaluated.  Of these patients 72% (46/64) were further evaluated and 39% (18/46) were found to have cardiac rhythm changes.  (Definity(R))<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Chest pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Abnormal ECGs, bradycardia, tachycardia, palpitation, hypertension, hypotension</p>
<p><b>Postmarketing reports</b>: Fatal cardiac arrest, shock, syncope, symptomatic arrhythmias (atrial fibrillation, tachycardia, bradycardia, supraventricular tachycardia, ventricular fibrillation/tachycardia), hypertension, hypotension<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Flushing</p>
<p><b>Uncommon</b> (0.1% to 1%): Pruritus, rash, erythematous rash, urticaria, increased sweating, dry skin<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea</p>
<p><b>Uncommon</b> (0.1% to 1%): Dyspepsia, dry mouth, tongue disorder, abdominal pain, diarrhea, vomiting<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain	</p>
<p><b>Uncommon</b> (0.1% to 1%): Arthralgia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache</p>
<p><b>Uncommon</b> (0.1% to 1%): Leg cramps, hypertonia, vertigo, paresthesia, dizziness, taste perversion</p>
<p>Postmarketing Reports: Coma, loss of consciousness, convulsion, seizure, transient ischemic attack, agitation, tremor, vision blurred, dizziness, headache, fatigue<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Renal pain<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Albuminuria<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Granulocytosis, leukocytosis, leukopenia, eosinophilia, hematoma<sup>[Ref]</sup></p><h3>Local</h3><p><b>Uncommon</b> (0.1% to 1%): Injection site reaction<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Conjunctivitis, abnormal vision<sup>[Ref]</sup></p><h3>Other</h3><p><b>Uncommon</b> (0.1% to 1%): Decreased hearing<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Coughing, hypoxia, pharyngitis, rhinitis, dyspnea</p>
<p><b>Postmarketing reports</b>: Fatal respiratory arrest, dyspnea, hypoxia, respiratory distress, stridor, wheezing<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Anaphylactic/anaphylactoid reactions<sup>[Ref]</sup></p><p>Postmarketing reports of anaphylactic/anaphylactoid reactions have included: anaphylactic shock, hypersensitivity, bronchospasm, throat tightness, angioedema, edema (pharyngeal, palatal, mouth, peripheral, localized), swelling (face, eye, lip, tongue, upper airway), facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema.<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Definity (perflutren)." Lantheus Medical Imaging Inc, North Billerica, MA. </p><p id="ref_3">3. "Product Information. Optison (perflutren)." Mallinckrodt Medical Inc, St. Louis, MO. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Optison (perflutren)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: ultrasound contrast media</li>
<li>FDA Alerts (2)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Optison &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Definity</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Echocardiography</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to perflutren: intravenous suspension</i></p><h3>General</h3><p>The most frequently reported adverse reactions were headache, nausea and/or vomiting, warm sensation or flushing, dizziness, and back pain.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Serious but uncommon cardiopulmonary reactions, including fatalities, have been reported during or following administration of this medication.  Most serious reactions occurred within 30 minutes of administration.</p><p></p><p>QTc prolongation of greater than 30 milliseconds occurred in 29% (64/221) of patients evaluated.  Of these patients 72% (46/64) were further evaluated and 39% (18/46) were found to have cardiac rhythm changes.  (Definity(R))<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Chest pain</p><p><b>Uncommon</b> (0.1% to 1%): Abnormal ECGs, bradycardia, tachycardia, palpitation, hypertension, hypotension</p><p><b>Postmarketing reports</b>: Fatal cardiac arrest, shock, syncope, symptomatic arrhythmias (atrial fibrillation, tachycardia, bradycardia, supraventricular tachycardia, ventricular fibrillation/tachycardia), hypertension, hypotension<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Flushing</p><p><b>Uncommon</b> (0.1% to 1%): Pruritus, rash, erythematous rash, urticaria, increased sweating, dry skin<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea</p><p><b>Uncommon</b> (0.1% to 1%): Dyspepsia, dry mouth, tongue disorder, abdominal pain, diarrhea, vomiting<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain	</p><p><b>Uncommon</b> (0.1% to 1%): Arthralgia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache</p><p><b>Uncommon</b> (0.1% to 1%): Leg cramps, hypertonia, vertigo, paresthesia, dizziness, taste perversion</p><p>Postmarketing Reports: Coma, loss of consciousness, convulsion, seizure, transient ischemic attack, agitation, tremor, vision blurred, dizziness, headache, fatigue<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Renal pain<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Albuminuria<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Granulocytosis, leukocytosis, leukopenia, eosinophilia, hematoma<sup>[Ref]</sup></p><h3>Local</h3><p><b>Uncommon</b> (0.1% to 1%): Injection site reaction<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Conjunctivitis, abnormal vision<sup>[Ref]</sup></p><h3>Other</h3><p><b>Uncommon</b> (0.1% to 1%): Decreased hearing<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Coughing, hypoxia, pharyngitis, rhinitis, dyspnea</p><p><b>Postmarketing reports</b>: Fatal respiratory arrest, dyspnea, hypoxia, respiratory distress, stridor, wheezing<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Anaphylactic/anaphylactoid reactions<sup>[Ref]</sup></p><p>Postmarketing reports of anaphylactic/anaphylactoid reactions have included: anaphylactic shock, hypersensitivity, bronchospasm, throat tightness, angioedema, edema (pharyngeal, palatal, mouth, peripheral, localized), swelling (face, eye, lip, tongue, upper airway), facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema.<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Definity (perflutren)." Lantheus Medical Imaging Inc, North Billerica, MA. </p><p id="ref_3">3. "Product Information. Optison (perflutren)." Mallinckrodt Medical Inc, St. Louis, MO. </p><h2>More about Optison (perflutren)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: ultrasound contrast media</li>
<li>FDA Alerts (2)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Optison &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Echocardiography</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>